Dr. McKay Discusses the CheckMate-214 Trial in RCC
Rana R. McKay, MD
Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma (RCC).
The phase III CheckMate-214 study evaluated the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with metastatic clear cell RCC.
This was the first time that an agent had beat sunitinib (Sutent) in the first-line space, says McKay, but there is still a lot to be learned with this combination regarding patient selection.